Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. (Q51280414)
Jump to navigation
Jump to search
scientific article published on 15 August 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. |
scientific article published on 15 August 2016 |
Statements
1 reference
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. (English)
1 reference
Markolf Hanefeld
1 reference
Julio Rosenstock
1 reference
George Grunberger
1 reference
Ronnie Aronson
1 reference
PierMarco Piatti
1 reference
Pierre Serusclat
1 reference
Xi Cheng
1 reference
Tianyue Zhou
1 reference
Elisabeth Niemoeller
1 reference
Elisabeth Souhami
1 reference
LixiLan-O Trial Investigators
1 reference
15 August 2016
1 reference
1 reference
39
1 reference
2026-2035
1 reference
11
1 reference
Identifiers
1 reference
1 reference